[go: up one dir, main page]

AU2001264474A1 - Admantane derivatives - Google Patents

Admantane derivatives

Info

Publication number
AU2001264474A1
AU2001264474A1 AU2001264474A AU6447401A AU2001264474A1 AU 2001264474 A1 AU2001264474 A1 AU 2001264474A1 AU 2001264474 A AU2001264474 A AU 2001264474A AU 6447401 A AU6447401 A AU 6447401A AU 2001264474 A1 AU2001264474 A1 AU 2001264474A1
Authority
AU
Australia
Prior art keywords
admantane
derivatives
sup
pharmaceutical compositions
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001264474A
Inventor
Lilian Alcaraz
Mark Furber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2001264474A1 publication Critical patent/AU2001264474A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

The invention provides compounds of general formula (I) in which m, A, R<SUP>1 </SUP>and Ar have the meanings defined in the specification; a process for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy.
AU2001264474A 2000-06-07 2001-06-01 Admantane derivatives Abandoned AU2001264474A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0013737 2000-06-07
GBGB0013737.2A GB0013737D0 (en) 2000-06-07 2000-06-07 Novel compounds
PCT/SE2001/001257 WO2001094338A1 (en) 2000-06-07 2001-06-01 Admantane derivatives

Publications (1)

Publication Number Publication Date
AU2001264474A1 true AU2001264474A1 (en) 2001-12-17

Family

ID=9893073

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001264474A Abandoned AU2001264474A1 (en) 2000-06-07 2001-06-01 Admantane derivatives

Country Status (8)

Country Link
US (1) US6949539B2 (en)
EP (1) EP1292590B1 (en)
JP (1) JP2004506611A (en)
AT (1) ATE316083T1 (en)
AU (1) AU2001264474A1 (en)
DE (1) DE60116761T2 (en)
GB (1) GB0013737D0 (en)
WO (1) WO2001094338A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI258462B (en) 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
WO2003042190A1 (en) * 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
SE0103836D0 (en) 2001-11-16 2001-11-16 Astrazeneca Ab Novel compounds
FR2836618B1 (en) * 2002-02-28 2004-04-16 Snecma Services THERMAL PROJECTION INSTRUMENT
SE0200920D0 (en) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
SE0300480D0 (en) * 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
EP1644042A1 (en) * 2003-05-29 2006-04-12 AstraZeneca AB A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate
US20070010497A1 (en) * 2003-05-29 2007-01-11 Nigel Boughton-Smith Pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
TW200507829A (en) * 2003-05-29 2005-03-01 Astrazeneca Ab New combination
GB0312609D0 (en) * 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
KR100554155B1 (en) * 2003-06-09 2006-02-22 학교법인 포항공과대학교 Electrode structure using metal / semiconductor nanorod heterostructure and manufacturing method thereof
SE0302139D0 (en) * 2003-07-28 2003-07-28 Astrazeneca Ab Novel compounds
SE0302192D0 (en) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
SE0302488D0 (en) * 2003-09-18 2003-09-18 Astrazeneca Ab New combination
US20080287467A1 (en) * 2004-05-06 2008-11-20 Gen Tamura Therapeutic Agent for Respiratory Diseases
US7241776B2 (en) * 2004-08-02 2007-07-10 Abbott Laboratories Cyanoamidine P2X7 antagonists for the treatment of pain
SA05260265A (en) * 2004-08-30 2005-12-03 استرازينيكا ايه بي Novel compounds
SE0402925D0 (en) * 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds
MX2009005478A (en) 2006-11-27 2009-08-12 Lundbeck & Co As H Heteroaryl amide derivatives.
CA2680761A1 (en) 2007-03-22 2008-09-25 Astrazeneca Ab Quinoline derivatives for the treatment of inflammatory diseases
EP2592082A1 (en) 2007-04-10 2013-05-15 H. Lundbeck A/S Heteroaryl amide analogues as p2x7 antagonists
PE20091036A1 (en) 2007-11-30 2009-08-15 Astrazeneca Ab QUINOLINE DERIVATIVE AS ANTAGONIST OF THE P2X7 RECEPTOR
NZ587799A (en) 2008-03-25 2012-06-29 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
EP2243772B1 (en) 2009-04-14 2012-01-18 Affectis Pharmaceuticals AG Novel P2X7R antagonists and their use
CN102858741A (en) 2010-05-14 2013-01-02 阿费克蒂斯制药股份公司 Novel methods for the preparation of P2X7R antagonists
JP2013249256A (en) * 2010-09-15 2013-12-12 Astellas Pharma Inc Fat liver disease therapeutic agent
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
CN103687860B (en) 2011-07-22 2016-06-08 埃科特莱茵药品有限公司 Heterocyclic amide derivatives as P2X7 receptor antagonists
BR112014017735B1 (en) 2012-01-20 2022-06-28 Idorsia Pharmaceuticals Ltd HETEROCYCLIC AMIGO-DERIVED COMPOUNDS AS P2X7 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, AND, USE OF A COMPOUND
JP6295269B2 (en) 2012-12-12 2018-03-14 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Indole carboxamide derivatives as P2X7 receptor antagonists
JP6295270B2 (en) 2012-12-18 2018-03-14 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Indole carboxamide derivatives as P2X7 receptor antagonists
ES2616114T3 (en) 2013-01-22 2017-06-09 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as P2X7 receptor antagonists
US9388198B2 (en) 2013-01-22 2016-07-12 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as P2X7 receptor antagonists

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3352912A (en) 1963-07-24 1967-11-14 Du Pont Adamantanes and tricyclo[4. 3. 1. 1 3.8] undecanes
US3471491A (en) 1967-08-28 1969-10-07 Squibb & Sons Inc Adamantyl-s-triazines
US3464998A (en) * 1968-03-04 1969-09-02 Searle & Co Adamantyl esters and amides of pyridinecarboxylic acids
GB1274652A (en) 1968-08-27 1972-05-17 Lilly Industries Ltd Adamantanyl-alkylamine derivatives and their preparation
IL53441A0 (en) 1977-11-22 1978-01-31 Teva Pharma Methyladamantyl hydrazines their preparation and pharmaceutical compositions containing them
US4751292A (en) 1985-07-02 1988-06-14 The Plant Cell Research Institute, Inc. Adamantyl purines
SG52229A1 (en) 1993-08-10 1998-09-28 Black James Foundation Gastrin and cck receptor ligands
FR2761358B1 (en) 1997-03-27 1999-05-07 Adir NOVEL N-ARYL PIPERIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
SE9704545D0 (en) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704544D0 (en) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
CA2368829A1 (en) 1999-04-09 2000-10-19 Astrazeneca Ab Adamantane derivatives
SE0103836D0 (en) 2001-11-16 2001-11-16 Astrazeneca Ab Novel compounds
SE0200920D0 (en) 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
WO2001094338A1 (en) 2001-12-13
US20030187031A1 (en) 2003-10-02
EP1292590B1 (en) 2006-01-18
EP1292590A1 (en) 2003-03-19
ATE316083T1 (en) 2006-02-15
DE60116761D1 (en) 2006-04-06
GB0013737D0 (en) 2000-07-26
JP2004506611A (en) 2004-03-04
US6949539B2 (en) 2005-09-27
DE60116761T2 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
AU2001264474A1 (en) Admantane derivatives
MY136430A (en) N-adamantylmethyl derivatives, pharmaceutical compositions containing them and processes for their preparation
PL366198A1 (en) Novel compounds
HK1042091A1 (en) Adamantane derivatives
PL358281A1 (en) Novel compounds
HK1046527A1 (en) Adamantane derivatives
AU2002359122A1 (en) Novel compounds
MXPA05008690A (en) Adamantane derivatives, processes for their preparation and pharmaceutical composition containing them.
WO2001046200A8 (en) Novel piperidine and piperazine derivatives
AU2002305143A1 (en) Pyrazolo&#39;1,5-a!pyridine derivatives
AU2002239344A1 (en) Pyrazolopyridines
MXPA04005347A (en) Pyrimidine derivatives as modulators of insuline-like growth factor-1 receptor (igf-i).
MY134892A (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use
SE0200920D0 (en) Novel compounds
SE9901875D0 (en) Novel compounds
DE602004011966D1 (en) Heterocyclylverbindungen
AU2002239348A1 (en) Pyrazolopyridine derivatives
IL164974A0 (en) Novel compounds and their use
GB0109122D0 (en) Novel compounds
GB0104050D0 (en) Chemical compounds
SE0101038D0 (en) Novel compounds
GB0120461D0 (en) Novel compounds
AU2002357740A1 (en) Pyrazolo-pyridine derivatives as antiherpes agents
AU2002248531A1 (en) Pyrazolopyriadine derivatives
SE0202693D0 (en) Compounds